Why the application of IVIG might be beneficial in patients with COVID-19.

Kindgen-Milles, Detlef; Feldt, Torsten; Jensen, Bjoern Erik Ole; Dimski, Thomas; Brandenburger, Timo

Kindgen-Milles, Detlef; Feldt, Torsten; Jensen, Bjoern Erik Ole; Dimski, Thomas; Brandenburger, Timo.

Afiliação

Kindgen-Milles D; Department of Anesthesiology, University Hospital Duesseldorf and Medical Faculty, Heinrich Heine University, 40225 Duesseldorf, Germany.
Feldt T; Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf and Medical Faculty, Heinrich Heine University, 40225 Duesseldorf, Germany.
Jensen BEO; Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf and Medical Faculty, Heinrich Heine University, 40225 Duesseldorf, Germany.
Dimski T; Department of Anesthesiology, University Hospital Duesseldorf and Medical Faculty, Heinrich Heine University, 40225 Duesseldorf, Germany.
Brandenburger T; Department of Anesthesiology, University Hospital Duesseldorf and Medical Faculty, Heinrich Heine University, 40225 Duesseldorf, Germany. Electronic address: timo.brandenburger@med.uni-duesseldorf.de.

Lancet Respir Med ; 10(2): e15, 2022 02.

Article em En | MEDLINE | ID: mdl-35120611

Assuntos

COVID-19; Imunoglobulinas Intravenosas; Humanos; SARS-CoV-2; Índice de Gravidade de Doença

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoglobulinas Intravenosas / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google